Indication

Peripheral T-cell lymphoma

Peripheral T-cell lymphoma (PTCL) represents a biologically heterogeneous group of aggressive non-Hodgkin lymphomas arising from mature, post-thymic T lymphocytes or natural killer (NK) cells. Read more about Peripheral T-cell lymphoma

11 drugs 9 manufacturers

Advertisement

Drugs that treat it

Common Peripheral T-cell lymphoma therapies.

Showing 1–9 of 11 drugs

PRALATREXATE

FOLATE ANTAGONISTS·PERIPHERAL T-CELL LYMPHOMA
FRESENIUS KABI
Filter & compare in the drug finder →Opens the drug finder with Peripheral T-cell lymphoma preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Peripheral T-cell lymphoma.

Peripheral T-cell lymphoma (PTCL) represents a biologically heterogeneous group of aggressive non-Hodgkin lymphomas arising from mature, post-thymic T lymphocytes or natural killer (NK) cells.

The condition primarily impacts the lymphatic and immune systems, typically presenting in older adults with widespread lymphadenopathy, frequent extranodal organ involvement (such as the liver, spleen, bone marrow, and skin), and systemic B symptoms.

Pathophysiologically, PTCL is characterized by clonal expansion driven by recurrent genetic and epigenetic alterations, dysregulation of T-cell receptor signaling pathways, and profound remodeling of the tumor microenvironment.

Clinically, these malignancies often follow a rapid, invasively progressive course with high relapse rates and historically poor long-term outcomes compared to their B-cell counterparts.

Personalize your experience

Follow Peripheral T-cell lymphoma and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it